A randomized control study of titrated and oral misoprostol solution for induction of labor at term

Barbie Sharma*, Tapasya Dhar, Sunita Goyal

INTRODUCTION

Induction of labor is a commonly practiced obstetric intervention to artificially initiate the process of labor when benefits to either mother or fetus outweigh those of pregnancy continuation. The incidence for labor induction dramatically varies between 8-44% and has shown a gradual increase in recent years. Administration of pharmacological agents like oxytocin, prostaglandin analogues, smooth muscle stimulants such as herbs or castor oil, mechanical methods such as digital stretching of the cervix and sweeping of the membranes, hygroscopic cervical dilators like laminaria tents, extra-amniotic balloon catheters and artificial rupture of membranes.

Presently prostaglandins, such as dinoprostone (PGE$_2$) and misoprostol (PGE$_1$), are used as most potent and acceptable methods for cervical ripening and labor induction. Oral misoprostol has been shown to be as effective as vaginal misoprostol and has the advantage of...
being more acceptable to women and can be self-administered.\textsuperscript{4}

In 2012, the International Federation of Gynecology and Obstetrics (FIGO) recommended an oral dose of 25 mcg misoprostol solution every 2 hours to induce labor, citing the 2011 World Health Organization (WHO) recommendations for labor induction.\textsuperscript{1,2} The WHO strongly recommended this regimen, rating the quality of evidence as moderate using the data from the 2006 Cochrane review by Alfvevic.\textsuperscript{3}

Absorption of "misoprostol" by oral route is known to be more rapid and predictable with terminal half-life of 20–40 minutes.\textsuperscript{5} Peak concentrations are achieved in 34 minutes followed by a rapid decline to low levels during the period of 120 minutes, and no drug accumulation phenomenon. Thus the administration of oral misoprostol in titrated doses may provide a steady drug serum level with better efficacy in less time with improved clinical outcome of induction as compared to two hourly dosing.

Our objective in this study was to evaluate effectiveness and safety of titrated oral misoprostol solution (OMS) in comparison with static-dose oral misoprostol solution (OMS) for induction of labor at term.

**METHODS**

**Study design**

This comparative randomized study was conducted in the Department of Obstetrics and Gynecology, Christian Medical College and Hospital, Ludhiana for a period of one year from 1\textsuperscript{st} December, 2017 to 30\textsuperscript{th} November, 2018. The study group comprised of all antenatal women admitted in labor room at term for induction of labor. Informed consent was taken for all selected women. Women were subjected to detailed history taking, a complete physical examination including per vaginum examination (to calculate modified bishop’s score and to rule out cephalopelvic disproportion), investigations and a NST. Gestational age was established by the first date of the last menstrual period and confirmed by first trimester ultrasound. Presentation was confirmed by palpation and third trimester ultrasound.

**Inclusion criteria**

Singleton live pregnancy; ≥37 weeks gestation; cephalic presentation; reactive NST; modified Bishop’s score ≤6.

**Exclusion criteria**

Hypersensitivity to misoprostol; uterine scar due to previous cesarean section or other uterine surgery; grand multipara; multiple gestations; high risk pregnancies, preeclampsia with severe features, significant maternal cardiac, renal, liver disease; any contraindication to induction and vaginal delivery e.g. cephalopelvic disproportion, malpresentation, fetal compromise and ante partum haemorrhage; Intrauterine fetal demise

**Randomization**

Women were randomized (1:1) into the treatment groups A) titrated-dose OMS group B) static dose OMS group; using computer generated number sequence. Allocation concealment was carried out by using opaque envelopes that were distributed by the obstetrics nurse. Whereas study investigators and attending care teams were aware of the allocated arm, patients were kept blinded to the allocation. Study investigators and outcome assessors could not be blinded as the data collection and analysis included outcome measures like timing of oral misoprostol solution doses.

**Patient and public involvement**

It was not appropriate or possible to involve patients or the public in the design, conduct, reporting or dissemination plans of our research.

**Study interventions**

Women after randomization were allocated into two groups after informed consent. The first group (A) was induced with hourly titrated oral misoprostol regimen and the second group (B) received two hourly static oral misoprostol regimen. Once labor had started, vital signs, fetal heart rate (FHR) and uterine activity were closely monitored during first stage of labor according to institutional protocols. Per vaginum examination was done 4-hourly or as indicated.

Procedure was ceased at any time when one of the following criteria was reached: 1) regular uterine contractions every 3-5 minutes and lasting 60 seconds or more; 2) dilatation of cervix reached 2.0 cm; 3) uterine tachysystole; 4) non-reassuring fetal status 5) completed dose regimen. If contractions subsequently become inadequate, artificial rupture of membranes was done and/or oxytocin was started ≥2 hours after the last misoprostol dose according to the discretion of the attending consultant.

**Method of preparation of oral misoprostol solution:** Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 μg) was pulverized and dissolved into 200 ml water. Thus 1 ml of solution had 1 μg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.

**Method of administration**

**Titrated OMS group:** All the women enrolled into the group A were given oral misoprostol solution according to the regimen described by Wang et al.\textsuperscript{10}
Static OMS group: In group B, the recommended FIGO regimen was used. Oral misoprostol solution 25 μg (25 ml) was administered every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity.

**Study outcome**

Primary outcome was induction to delivery time.

Secondary Outcomes were major maternal and fetal complications which pertained to safety and efficacy of regimens.

**Efficacy**

This included mean gestational age, indication of induction of labor, mean change in Bishop’s score, total number of misoprostol doses required, time taken to complete doses, mean total dose of misoprostol required, indication for stopping drug regimen, mean interval from induction to onset of labor, mode of delivery, indication for LSCS, oxytocin augmentation.

**Maternal morbidity**

This included incidence of tachysystole, fever-intrapartum and postpartum, puerperal sepsis, uterine rupture.

**Neonatal parameters**

Neonatal parameters such as incidence of meconium-stained liquor, APGAR scores at 1, 5 minutes and NICU stay.

**Sample size calculation**

The sample size by using the clinical data was 132 for each group. Required sample size of 264 for the study was calculated using the formula:

\[
\text{Sample size} = (r+1) \frac{(p^*)(1-p^*)}{r^2(p_1-p_2)} \times 2
\]

Where,

- \(Z_{1-\alpha/2}=1.96\), is standard normal deviate at type 1 error \(\alpha = 0.05\),
- \(Z_{1-\beta}=0.84\) is standard normal deviate at 80% power,
- \(r\) is ratio of cases, in case of equal number it is 1,
- \(p^* = \text{average proportion exposed} = \frac{\text{proportion of exposed cases in group 1} + \text{proportion of exposed cases in group 2}}{2}\)
- \(p_1-p_2\) = Effect size or difference in proportion expected based on previous study.

**RESULTS**

Our study population in both the groups had similar demographic profile with no significant differences with regards to maternal age, parity and gestational age. The mean gestational age of the patients at the onset of study was 38.65±1.19 weeks in the hourly titrated dose group and 38.83±1.12 weeks in the two hourly static dose group of patients (\(p>0.10, \text{NS}\)). The most common indication for induction in both the groups was elective induction with 32.6% (n=43) in group A and 29.6% (n=29) in group B.
followed by prelabor rupture of membranes (17.4% and 12.1% respectively) (p>0.10, NS).

The mean change in modified Bishop’s Score was 3.51±1.14 in the hourly titrated-dose group and 3.52±1.14 in the two hourly static dose group which was not significant statistically. Most of the women were given 5 doses in the hourly titrated-dose group and 4 doses in the two hourly static dose group with a mean of 4.95±2.19 in group A and 4.39±2.09 in group B (p>0.10, NS). However, 44.7% of women in group A took 4 hours to receive required number of doses to give into labor as compared to 18.2% women in group B (p<0.01, SS). A significantly higher number of women took 9-12 hours to receive required number of doses in group B (26.5 %) than women in group A (8.3 %) (p<0.01, SS). Maximum time of 10.5 hours (9 doses) was taken by 3.5% women in the hourly titrated dose group and 3.52±1.14 in the two hourly static dose group which was not significant statistically. Most of the patients with maximum dose of 12 mU/minute. 76.5% women in the hourly titrated dose group required oxytocin as compared to 59.8% in the two hourly static dose group (p<0.05, SS).

86 women (65.2%) in the hourly titrated-dose group had vaginal delivery as compared to 89 women (67.4%) in the two hourly static dose group (p>0.10, NS). The mean interval between induction and delivery was 16.19±10.48 hours in group A and 15.28±8.34 hours in group B (p>0.10, NS). 36 women (41.9%) delivered vaginally within 12 hours, 35 women (40.7%) in 12-24 hours and 15 women (17.4%) took more than 24 hours to deliver with titrated regimen. In group B with static regimen, 32 women (36.0%) had vaginal delivery in 12 hours, 40 women (44.9%) in 12-24 hours and 17 women (19.1%) took more than 24 hours. (p>0.10, NS). Remaining 46 women (34.8%) in group A and 43 women (32.6%) in group B had LSCS. The most common indication for cesarean section in titrated dose group was MSAF in early labor in 13 women (28.3%) while in group B it was secondary arrest of dilatation in 14 women (32.6%) (p<0.10, NS). Overall incidence of meconium stained amniotic fluid was noted in 17 women (12.9%) in group A as compared to 15 women (11.4%) in group B with no significant difference (p>0.10, NS).

Table 1: Trial profile and outcomes.

| Variable                         | Hourly misoprostol | 2 hourly misoprostol | P value |
|----------------------------------|--------------------|----------------------|---------|
| Age, years                       | 27.39±3.56        | 27.40±2.83           | >0.10   |
| Gestation, weeks                 | 38.65±1.19        | 38.83±1.12           | >0.10   |
| Nulliparous                      | 60.6%              | 56.8%                | >0.10   |
| Bishop score ≤3 before induction | 18.2%              | 22%                  | >0.10   |
| Change in modified bishop score  | 3.51±1.14         | 3.52±1.14            | >0.10   |
| Total misoprostol dosage         | 144.47±89.86      | 110.23±52.14         | <0.05   |
| Mean number of doses             | 4.95±2.19         | 4.39±2.09            | >0.10   |
| Delivered vaginally in ≤24 hours | 53.8%              | 54.5%                | >0.10   |
| Cesarean section                 | 34.8%              | 32.6%                | >0.10   |
| Oxytocin                         |                    |                      |         |
| Yes                              | 76.5%              | 59.8%                | <0.05   |
| No                               | 23.5%              | 40.2%                |         |

Table 2: Distribution of cases according to time taken to give required doses.

| Time taken to give required doses (hours) | Hourly misoprostol | 2 hourly misoprostol | P value |
|------------------------------------------|--------------------|----------------------|---------|
| 1-4                                      | 59                 | 44.7                 | 18.2    |
| 5-8                                      | 62                 | 47                   | 54      |
| 9-12                                     | 11                 | 8.3                  | 35      |
| ≥13                                      | 0                  | 0                    | 19      |
| Total                                    | 132               | 100                  | 132     |

The mean interval between induction and onset of labor was 7.96±6.76 hours in group A and 7.10±5.26 hours in group B (p>0.10, NS). Oxytocin augmentation was required in most of the patients with maximum dose of 12 mU/minute. 76.5% women in the hourly titrated dose group required oxytocin as compared to 59.8% in the two hourly static dose group (p<0.05, SS).

Table 3: Maternal morbidity.

| Variable                       | Hourly misoprostol | 2 hourly misoprostol | P value |
|-------------------------------|--------------------|----------------------|---------|
| Uterine hyperstimulation/ tachysystole | 1.5%               | 0                    | >0.10   |
| Intrapartum fever              | 1.5%               | 0                    | >0.10   |
| Postpartum fever               | 6.1%               | 6.8%                 | >0.10   |
| Puerperal sepsis               | 0                  | 0                    | >0.10   |
| Uterine rupture                | 0                  | 0                    | >0.10   |
No incidence of puerperal sepsis and uterine rupture and was seen in both the groups. The only complications noted were intrapartum fever, postpartum fever and uterine contraction abnormality. Intrapartum fever and uterine contraction abnormality was seen in 1.5% in hourly titrated dose group. 6.1% had postpartum fever in hourly titrated dose group as compared to 6.8% in two hourly static dose group (p>0.10, NS). NICU stay was required in 5 (3.8%) cases in both the groups. 0.76% cases had Apgar score <7 in group B. There was no significant difference observed in neonatal outcomes in the two groups.

**DISCUSSION**

Hourly titrated regimen of oral misoprostol solution can decrease the time and drug dosage required for induction of labor as compared to static two hourly regimen, thereby decreasing the time taken from induction to delivery. In our study, titrated oral misoprostol dose regimen has been found to have comparable efficacy to static oral misoprostol dose regimen. Vaginal delivery was achieved in a total of 86 women (65.2%) with hourly titrated dose regimen and in 89 (67.4%) women with two hourly static regimen. 71 (53.8%) women in group A and 72 (54.5%) women in group B had vaginal delivery within 24 hours. These observations were comparable to a study by Rouzi et al in which 64.4% women in the hourly titrated dose group and 65.8% in the two hourly static dose group delivered vaginally within 24 hours. Similarly, it was noted that a significantly higher number of women (79.7%) delivered vaginally within 24 hours with titrated oral misoprostol in a study conducted by Aalami-Harandi and colleagues.11 Study reported by Cheng and colleagues also noted higher vaginal delivery rate of 96.0% with titrated oral misoprostol regimen out of which 94.1% delivered within 24 hours. There was no statistically significant difference found with respect to outcomes like time taken from induction to onset of labor, time taken from induction to delivery time, number of doses required and change in modified Bishop score in our study.

The median total misoprostol dosage requirement was noted to be higher in the titrated group than the static group. Incidence of cesarean section was similar in both the groups in our study (34.8% and 32.6%) (p>0.10).

Need for augmentation by oxytocin was also higher in titrated group as compared to static oral misoprostol group. Intrapartum fever and uterine contraction abnormality were seen in 2 women (1.5% each) in group A and postpartum fever was seen in 8 women (6.1%). Incidence of postpartum fever in group B was 6.8% (9 women). Incidence of meconium stained amniotic fluid was also found to be similar in both the groups. It is thus be noteworthy that the incidence rates for all adverse outcomes associated with titrated and static oral misoprostol dose regimens were of similar magnitude.

**Comparison with other studies**

Hourly titrated regimen of oral misoprostol solution can decrease the time and drug dosage required for induction of labor as compared to static two hourly regimen, thereby decreasing the time taken from induction to delivery. In our study, titrated oral misoprostol dose regimen has been found to have comparable efficacy to static oral misoprostol dose regimen. Vaginal delivery was achieved in a total of 86 women (65.2%) with hourly titrated dose regimen and in 89 (67.4%) women with two hourly static regimen. 71 (53.8%) women in group A and 72 (54.5%) women in group B had vaginal delivery within 24 hours. These observations were comparable to a study by Rouzi et al in which 64.4% women in the hourly titrated dose group and 65.8% in the two hourly static dose group delivered vaginally within 24 hours. Similarly, it was noted that a significantly higher number of women (79.7%) delivered vaginally within 24 hours with titrated oral misoprostol in a study conducted by Aalami-Harandi and colleagues.11 Study reported by Cheng and colleagues also noted higher vaginal delivery rate of 96.0% with titrated oral misoprostol regimen out of which 94.1% delivered within 24 hours. There was no statistically significant difference found with respect to outcomes like time taken from induction to onset of labor, time taken from induction to delivery time, number of doses required and change in modified Bishop score in our study.

The median total misoprostol dosage requirement was noted to be higher in the titrated group than the static group. Aduloju and colleagues also reported greater misoprostol requirement in titrated group as compared to static group with median dose of 180 µg (range 60-720 µg) and 150 µg (range 25-275 µg) in each group respectively. Similar dosage was observed in studies by Rouzi et al, Aalami-Harandi and colleagues and Cheng with higher misoprostol requirement by women in titrated group.6,9,11 Number and overall misoprostol dose requirement in both titrated and static groups were higher in all these studies as compared to the present study.

Incidence of cesarean section was similar in both the groups in our study (34.8% and 32.6%) (p>0.10). A lower caesarean delivery rate of 21.3% in titrated group and 20.0% in static group was observed by Aduloju and colleagues. Cheng and colleagues had earlier reported even lower caesarean delivery rate in their study in 2008 with titrated group. The caesarean section rate of 23.2% in titrated group was comparable to our study. Rouzi et al had also reported lower cesarean section rates as compared to our study (23.2% and 8.2% respectively).6 Need for

---

**Table 4: Fetal parameters.**

| Variable                        | Hourly misoprostol | 2 hourly misoprostol | P value |
|---------------------------------|--------------------|----------------------|---------|
| Non-reassuring fetal heart rate | 1.5%               | 0                    | >0.10   |
| Meconium-stained fluid         | 12.9%              | 11.4%                | >0.10   |
| Intrauterine pneumonia         | 0                  | 0.76%                | >0.10   |
| Birth weight, gm               | 3049.6±422.4       | 3037.6±441.7         | >0.10   |
| Apgar score <7 at 1 minute     | 0                  | 0.76%                | >0.10   |
| Apgar score <7 at 5 minutes    | 0                  | 0.76%                | >0.10   |
| NICU admission                 | 3.8%               | 3.8%                 | >0.10   |
augmentation by oxytocin was also higher in titrated group as compared to static oral misoprostol group. Oxytocin requirement was also higher in hourly titrated dose group (76.5%) as compared to two hourly static dose group (59.8%) (p<0.05). This was similar to the higher oxytocin requirement noted in 72.2% women in hourly titrated group and 75% in two hourly static group by Rouzi et al in 2017.6 Lesser number of women (31%) required oxytocin infusion in study conducted by Deshmukh and colleagues.7 Similarly, Aduloju and colleagues in had reported lower oxytocin requirement in both hourly titrated group (32%) and two hourly static group (30.7%).8 Cheng and colleagues had observed lowest oxytocin requirement by women in titrated group (10.9%).9

**Strengths and limitations of this study**

Prospective recording of the data contributed to the strength of our study. Randomization of participants led to minimal allocation and selection bias with greater data reliability. Number of women enrolled in the study also helped to get high quality data. Nonetheless, the data was not extrapolated with respect to the parity of women and the results should therefore be interpreted with caution. We restricted the analysis to women at term without any co-morbid conditions limiting the possibility of confounding by these factors.

**CONCLUSION**

Although misoprostol fell into disrepute in view of effects like uterine contraction abnormality, non-reassuring fetal heart rate pattern and neonatal outcome with respect to meconium staining of amniotic fluid, however our study showed none of these effects to be significant. Shorter time interval is required to administer hourly titrated oral misoprostol regimen as compared to two hourly static oral misoprostol regimen to achieve similar results. To conclude, titrated oral misoprostol, considering its efficacy, safety and time saving is comparable to WHO recommended static oral misoprostol.

**ACKNOWLEDGMENTS**

We thank the Department of obstetrics and gynecology and neonatal intensive care unit (NICU), Christian medical college, Ludhiana for the support and data. A special thanks to all the women participating in the study.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved by the Institutional Ethics Committee Christian Medical College and Hospital, Ludhiana. (Approval number: 201801-018-IEC/CMCL-APPRVL-PG)

**REFERENCES**

1. Morris JL, Winikoff B, Dabash R, Weeks A, Faundes A, Gemzell-Danielsson K et al. FIGO’s updated recommendations for misoprostol used alone in gynecology and obstetrics. Int J Gynecol Obstet. 2017;138(3):363-6.
2. World Health Organization. WHO recommendations for induction of labour. Geneva: World Health Organization; 2011. Available from: https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241501156/en/. Accessed 20 December 2019.
3. Vogel JP, Osoti AO, Kelly AJ, Livio S, Norman JE, Alfirevic Z. Pharmacological and mechanical interventions for labour induction in outpatient settings. Cochrane Database Syst Rev. 2017(9).
4. Cheng SY, Hung CH, Lee MR, Chan TM. Pharmacokinetic analysis of hourly oral misoprostol administration—a pilot study. Pharm Anal Acta. 2015;6:415.
5. Weeks AD, Navaratnam K, Alfirevic Z. Simplifying oral misoprostol protocols for the induction of labour. BJOG. 2017;124(11):1642.
6. Rouzi AA, Alsahlly N, Alamoudi R, Almansouri N, Alsinani N, Alkafy S, et al. Randomized clinical trial between hourly titrated and 2 hourly static oral misoprostol solution for induction of labor. Am J Obstet Gynecol. 2017;216(4):405-e1.
7. Deshmukh VL, Rajamanya AV, Yelikar KA. Oral misoprostol solution for induction of labour. J Obstet Gynecol India. 2017;67(2):98-103.
8. Aduloju OP, Ipinnimo OM, Aduloju T. Oral misoprostol for induction of labor at term: a randomized controlled trial of hourly titrated and 2 hourly static oral misoprostol solution. J Matern Fet Neonat Med. 2019;1-7.
9. Cheng SY, Ming H, Lee JC. Titrated oral compared with vaginal misoprostol for labor induction: a randomized controlled trial. Obstet Gynecol. 2008;111(1):119-25.
10. Wang X, Yang A, Ma Q, Li X, Qin L, He T. Comparative study of titrated oral misoprostol solution and vaginal dinoprostone for labor induction at term pregnancy. Arch Gynecol Obstet. 2016;294(3):495-503.
11. Aalam-Harandi R, Karamali M, Moeini A. Induction of labor with titrated oral misoprostol solution versus oxytocin in term pregnancy: randomized controlled trial. Rev Bras Ginecol Obstet. 2013;35(2):60-5.

**Cite this article as:** Sharma B, Dhar T, Goyal S. A randomized control study of titrated and oral misoprostol solution for induction of labor at term. Int J Reprod Contracept Obstet Gynecol 2021;10:4206-11.